Quick Answer
Coya Therapeutics, Inc. reported Earnings Per Share Diluted of $1.27 (loss) per share for the year ending 2025.
- Coya Therapeutics, Inc. showed a decrease of -29.6% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Coya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $0.66 (loss) per share | Q2 2022: $1.32 (loss) per share | Q3 2022: $1.55 (loss) per share | Q1 2023: $0.28 (loss) per share | Q2 2023: $0.31 (loss) per share | Q3 2023: $0.34 (loss) per share | Q1 2024: $0.35 (loss) per share | Q2 2024: $0.19 (loss) per share | Q3 2024: $0.26 (loss) per share | Q1 2025: $0.44 (loss) per share | Q2 2025: $0.36 (loss) per share | Q3 2025: $0.13 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Coya Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 32.8%.
- Historical annual values: Fiscal year 2025: $1.27 (loss) per share | Fiscal year 2024: $0.98 (loss) per share | Fiscal year 2023: $0.79 (loss) per share | Fiscal year 2022: $4.73 (loss) per share | Fiscal year 2021: $1.89 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: